AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22551811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 μg HA and Matrix M adjuvant (50 μg)
Number of subjects: 60
Study 22551811 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg HA and Matrix M adjuvant (50 μg)
Number of subjects: 60
Study 22551811 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg HA and Matrix M adjuvant (50 μg)
Number of subjects: 60
Study 20973989 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective birth at 37 weeks gestation
Number of subjects: 460
Study 20973989 — intervention group
Group type: COMPARATOR
Intervention: Standard care (birth planned for 38 weeks gestation or later)
Number of subjects: 460
Study 18403736 — intervention group
Group type: EXPERIMENTAL
Intervention: DP‐b99 (1 mg/kg per day for 4 days)
Number of subjects: 150
Study 18403736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 18403736 — intervention group
Group type: EXPERIMENTAL
Intervention: DP‐b99
Number of subjects: 150
Study 16034832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissecting sealer
Number of subjects: 94
Study 16034832 — intervention group
Group type: COMPARATOR
Intervention: Clamp crushing method
Number of subjects: 94
Study 11808836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate (200 mg, oral administration)
Number of subjects: 15
Study 11808836 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 15
Study 10064252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg daily)
Number of subjects: 274
Study 7723301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride 50 mg intranasally
Number of subjects: 36
Study 7723301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride 126 mg intranasally
Number of subjects: 36
Study 7723301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweat patch technology
Number of subjects: 36
Study 7723301 — intervention group
Group type: COMPARATOR
Intervention: Nondrug users wearing patches
Number of subjects: 36
Study 1867149 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention for smoking cessation over 4 years
Number of subjects: 22
Study 1867149 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched pairs of communities)
Number of subjects: 22
Study 6355207 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day of amitriptyline
Number of subjects: 0
Study 6355207 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day of phenelzine
Number of subjects: 0
Study 31249253 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg administered sublingually 50 minutes before surgery
Number of subjects: 88
Study 31249253 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered sublingually 50 minutes before surgery
Number of subjects: 88
Study 29139325 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 0
Study 29139325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26718698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Number of subjects: 135
Study 26718698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 26718698 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 150mg
Number of subjects: 135
Study 24129964 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome pressure
Number of subjects: 0
Study 24129964 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring pressure
Number of subjects: 0
Study 24129964 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress appraisals
Number of subjects: 0
Study 24129964 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress reactivity (heart rate)
Number of subjects: 0
Study 22846236 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms, age, and past DAD behavior
Number of subjects: 655
Study 22846236 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' perceptions of peers' approval of DAD
Number of subjects: 655
Study 19110224 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 458
Study 19110224 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 150 mg/d
Number of subjects: 458
Study 19110224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 17718786 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg bid)
Number of subjects: 29
Study 17718786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16398436 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianggu capsules (QGC), 1 capsule (180 mg) each time, three times a day for three months
Number of subjects: 65
Study 16398436 — intervention group
Group type: COMPARATOR
Intervention: D-Cal Biocal, 2 tablets (1500 mg) each time, once daily for three months
Number of subjects: 65
Study 12593456 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 29
Study 12593456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9842630 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based system (FitLinxx Interactive Fitness Network)
Number of subjects: 164
Study 9842630 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise tracking and feedback
Number of subjects: 164
Study 8590616 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin (10 mg)
Number of subjects: 20
Study 8590616 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 2672380 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (200 mg/day p.o.)
Number of subjects: 80
Study 2672380 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 321863 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberin drops
Number of subjects: 12
Study 321863 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 12
Study 30327158 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal immobilization at 20°
Number of subjects: 140
Study 30327158 — intervention group
Group type: COMPARATOR
Intervention: Spinal immobilization at 0°
Number of subjects: 140
Study 26951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult patients (distressing behaviours)
Number of subjects: 63
Study 26951795 — intervention group
Group type: COMPARATOR
Intervention: Neutral patients
Number of subjects: 63
Study 26951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate reflection on cases
Number of subjects: 63
Study 26951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult patients
Number of subjects: 63
Study 26951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult and neutral patients
Number of subjects: 63
Study 26195056 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a every 2 weeks
Number of subjects: 1012
Study 26195056 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1012
Study 24196331 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (1319 nm, 1064 nm, and BroadBand Light)
Number of subjects: 21
Study 21530095 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of zinc sulfate orally in water daily for 6 weeks + one capsule of vitamin B-complex + one capsule of vitamin A or E (first 10 days)
Number of subjects: 30
Study 21530095 — intervention group
Group type: COMPARATOR
Intervention: Proposed placebo-controlled trials with incremental doses of zinc sulfate along with magnesium and selenium
Number of subjects: 30
Study 18505442 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopanoic acid (IA) 3 g/day for 7 days
Number of subjects: 14
Study 18505442 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole 30 mg/day for 1 month
Number of subjects: 14
Study 18505442 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 normal women)
Number of subjects: 14
Study 16920374 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (Group I)
Number of subjects: 4
Study 16920374 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (Group II)
Number of subjects: 4
Study 16920374 — intervention group
Group type: COMPARATOR
Intervention: Preterm controls (Group III)
Number of subjects: 4
Study 16920374 — intervention group
Group type: COMPARATOR
Intervention: Term controls (Group IV)
Number of subjects: 4
Study 12573307 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet [(3)H]paroxetine binding sites
Number of subjects: 0
Study 12573307 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter polymorphism (short deletion variant)
Number of subjects: 0
Study 12573307 — intervention group
Group type: COMPARATOR
Intervention: Allele or genotype frequency for the three polymorphisms
Number of subjects: 0
Study 11205093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nation-wide multifaceted intervention programme involving general practitioners (GPs)
Number of subjects: 988
Study 9135951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 0
Study 9135951 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic amino acids (L-arginine 2 g/day plus L-lysine 0.5 g/day)
Number of subjects: 0
Study 9135951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8031342 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (2 mg.ml‐1) with droperidol (0.2 mg.ml‐1)
Number of subjects: 60
Study 8031342 — intervention group
Group type: COMPARATOR
Intervention: morphine alone (2 mg.ml‐1)
Number of subjects: 60
Study 3003445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HTZ) administration, 25 mg 12-hrly for 18 days
Number of subjects: 6
Study 3003445 — intervention group
Group type: COMPARATOR
Intervention: Control days (no HTZ)
Number of subjects: 6
Study 31375620 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week muscle strengthening exercise intervention
Number of subjects: 0
Study 31375620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29079460 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS frequency group A (above IGF)
Number of subjects: 26
Study 29079460 — intervention group
Group type: COMPARATOR
Intervention: tACS frequency group B (below IGF)
Number of subjects: 26
Study 29079460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 26
Study 27875286 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula (IF) 400 mL/d for 10 days prior to surgery
Number of subjects: 38
Study 27875286 — intervention group
Group type: COMPARATOR
Intervention: Commonly used formula (CF)
Number of subjects: 38
Study 24759901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious group-based rejection (observing rejection of ingroup members)
Number of subjects: 0
Study 22357739 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vitamin D and calcium-fortified soft white cheese (2 servings of 100 g daily for 6 weeks)
Number of subjects: 71
Study 22357739 — intervention group
Group type: COMPARATOR
Intervention: Not consuming the fortified cheese (control group)
Number of subjects: 71
Study 20532660 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about Medicare's 'no pay for errors' rule
Number of subjects: 168
Study 20532660 — intervention group
Group type: COMPARATOR
Intervention: No information provided (control group)
Number of subjects: 168
Study 19037467 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 0
Study 16320709 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 100
Study 16320709 — intervention group
Group type: COMPARATOR
Intervention: Dextran treatment
Number of subjects: 100
Study 12923655 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated bovine colostrum protein (CBC) 60g/day for 8 weeks
Number of subjects: 174
Study 12923655 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (WP) for 8 weeks
Number of subjects: 174
Study 10586393 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous infusion (18 min)
Number of subjects: 27
Study 10586393 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg oral solution
Number of subjects: 27
Study 10586393 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg orally administered capsule
Number of subjects: 27
Study 8767364 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1328
Study 8767364 — intervention group
Group type: EXPERIMENTAL
Intervention: New guidelines for thrombolytic therapy
Number of subjects: 1328
Study 1841935 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 60 mg/kg
Number of subjects: 30
Study 1841935 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (NT)
Number of subjects: 30
Study 6350402 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (150, 300, or 600 IU/day)
Number of subjects: 75
Study 6350402 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 31759877 — intervention group
Group type: EXPERIMENTAL
Intervention: Teres major transfer to the infraspinatus tendon
Number of subjects: 20
Study 30121734 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 24
Study 30121734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28724862 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery (ES group, 25 teeth)
Number of subjects: 50
Study 28724862 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (C group, 25 teeth)
Number of subjects: 50
Study 28724862 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery (ES group)
Number of subjects: 50
Study 26414022 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat (50 mg/d)
Number of subjects: 263
Study 26414022 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat (125 mg/d)
Number of subjects: 263
Study 26414022 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat
Number of subjects: 263
Study 26414022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 26414022 — intervention group
Group type: COMPARATOR
Intervention: Avagacestat vs Placebo
Number of subjects: 263
Study 23617621 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified treatment (ModTx)
Number of subjects: 0
Study 23617621 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (StTx)
Number of subjects: 0
Study 23617621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21543538 — intervention group
Group type: COMPARATOR
Intervention: Controlled research meals with lower protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) reduced by 0.2 to 0.3 g · kg(‐1) · d(‐1))
Number of subjects: 112
Study 21543538 — intervention group
Group type: COMPARATOR
Intervention: Controlled research meals with higher protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) increased by 0.2 g · kg(‐1) · d(‐1))
Number of subjects: 112
Study 19056566 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium L-glutamate (MSG) added to a protein-rich liquid meal
Number of subjects: 10
Study 19056566 — intervention group
Group type: COMPARATOR
Intervention: Monosodium L-glutamate (MSG) added to a carbohydrate meal
Number of subjects: 10
Study 19056566 — intervention group
Group type: COMPARATOR
Intervention: Monosodium L-glutamate (MSG) added to noncaloric water
Number of subjects: 10
Study 16400050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate maize
Number of subjects: 60
Study 16400050 — intervention group
Group type: COMPARATOR
Intervention: Isohybrid wild-type maize
Number of subjects: 60
Study 16400050 — intervention group
Group type: COMPARATOR
Intervention: Local maize
Number of subjects: 60
Study 14722705 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 40
Study 14722705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11407289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg/kg i.v.
Number of subjects: 40
Study 11407289 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal 5 mg/kg i.v.
Number of subjects: 40
Study 9427902 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous phenobarbital therapy
Number of subjects: 9
Study 9427902 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 9
Study 9427902 — intervention group
Group type: COMPARATOR
Intervention: Intermittent diazepam
Number of subjects: 9
Study 9427902 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 9
Study 9427902 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 9
Study 7959558 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y anastomosis
Number of subjects: 94
Study 7959558 — intervention group
Group type: COMPARATOR
Intervention: Billroth II anastomosis
Number of subjects: 94
Study 3559333 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: rifampin 600 mg once a month for 6 months with dapsone 100 mg daily
Number of subjects: 0
Study 3559333 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II: same as Regimen I, supplemented with an additional 6 months' treatment with dapsone 100 mg daily
Number of subjects: 0
Study 3559333 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen III: same as Regimen II, with rifampin administered daily for the first 7 days
Number of subjects: 0
Study 3559333 — intervention group
Group type: COMPARATOR
Intervention: Regimen I
Number of subjects: 0
Study 3559333 — intervention group
Group type: COMPARATOR
Intervention: Regimen II
Number of subjects: 0
Study 3559333 — intervention group
Group type: COMPARATOR
Intervention: Regimen III
Number of subjects: 0
Study 31421394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% GS solution with 15% glucose
Number of subjects: 9
Study 31421394 — intervention group
Group type: COMPARATOR
Intervention: 25 mL of water (control) with 15% glucose
Number of subjects: 9
Study 31421394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% GS solution with 0.09% aspartame
Number of subjects: 9
Study 31421394 — intervention group
Group type: COMPARATOR
Intervention: 25 mL of water (control) with 0.09% aspartame
Number of subjects: 9
Study 28134330 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted triglyceride levels (C allele of rs662799 variant)
Number of subjects: 0
Study 28134330 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted triglyceride levels
Number of subjects: 0
Study 25159737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 12
Study 25159737 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 12
Study 25159737 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study 23124598 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal CUP
Number of subjects: 40
Study 23124598 — intervention group
Group type: COMPARATOR
Intervention: Breast CUP
Number of subjects: 40
Study 21519801 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) hemorrhoidectomy
Number of subjects: 210
Study 21519801 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy Milligan-Morgan hemorrhoidectomy (MMH)
Number of subjects: 210
Study 21519801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 210
Study 18477276 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 20
Study 17065029 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) for 6 months (6H)
Number of subjects: 2736
Study 17065029 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid plus rifampicin for 3 months (3HR)
Number of subjects: 2736
Study 17065029 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid plus rifampicin plus pyrazinamide for 3 months (3HRZ)
Number of subjects: 2736
Study 17065029 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months (PPD-positive)
Number of subjects: 2736
Study 17065029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (anergic)
Number of subjects: 2736
Study 15363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intravenous iron injection (100 mg of iron sucrose every 2 weeks)
Number of subjects: 19
Study 15363053 — intervention group
Group type: COMPARATOR
Intervention: Slow intravenous iron infusion (100 mg of iron sucrose every 2 weeks)
Number of subjects: 19
Study 15363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intravenous iron injection
Number of subjects: 19
Study 15363053 — intervention group
Group type: COMPARATOR
Intervention: Slow intravenous iron infusion
Number of subjects: 19
Study 11606146 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 250
Study 11606146 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 250
Study 11606146 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 250
Study 9931784 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy and modified radical neck dissection (n = 18)
Number of subjects: 40
Study 9931784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal thyroid resection (n = 10)
Number of subjects: 40
Study 9931784 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy (n = 12) partly with selective lymphadenectomy
Number of subjects: 40
Study 8087930 — intervention group
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP) infusion
Number of subjects: 11
Study 8087930 — intervention group
Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 11
Study 2489862 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed condition
Number of subjects: 10
Study 2489862 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy condition
Number of subjects: 10
Study 2489862 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed and accuracy condition
Number of subjects: 10
Study 31265187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 96
Study 31265187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (with PE)
Number of subjects: 96
Study 31265187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy expert (treatment provider)
Number of subjects: 96